Healthcare shares are mixed in pre-market, while Inovio
) is up more than 16% in pre-market trade after saying its DNA
Vaccine for the Middle East Syndrome coronavirus induced robust and
durable immune responses in a preclinical trial.
Since 2012, the MERS virus has killed 42% of those infected.
Inovio said that in the study, the vaccine constructs were
observed to induce strong neutralizing antibodies and broad CD8+ T
cells in mice. "These findings are vital given the importance of
neutralizing antibodies in preventing infection and the role T
cells play in clearing infection by killing cells that harbor the
virus," the company said in a statement.
And, in other major gainers in healthcare this morning, shares
of Unilife (
) are up 15.7% at $3.24 after Hikma Pharmaceuticals announced that
it has signed a long term commercial supply contract with the
company for the use of Unifill prefilled syringes with a range of
generic injectable drugs.
Under the 15-year global agreement, Unilife will supply Hikma
with customised prefillable delivery systems from its Unifill
platform. For the exclusive global rights to use Unilife's Unifill
products with a selection of Hikma's generic injectable products,
Hikma will pay a total of $40 million, comprising an upfront
payment of $5 million, an additional $15 million payment expected
during 2014 and a further $20 million in milestone-based payments
to be paid thereafter.
Unilife will commence product sales to Hikma in early 2014.